

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>for provisional applications under 37 C.F.R. § 1.53(b)</small>		Attorney Docket No. LUD 5538.1 CIP	
		First Inventor or Application Identifier CHEN et al.	
Title ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER ASSOCIATED ANTIGENS PER SE, AND USES THEREOF		Express Mail Label No. EJ474429960US	
<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> Transmittal Form (e.g., PTO/SB/17) <small>as an original and a duplicate for fee processing</small>		6. <input type="checkbox"/> Microfiche Computer Program (Appendix)	
2. <input checked="" type="checkbox"/> Specification <small>(preferred arrangement set forth below)</small> <div style="float: right;">Total Pages 33</div> <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Reference of Microfiche Appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul>		7. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, see necessary)</small> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer Readable Copy</li> <li>b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)</li> <li>c. <input type="checkbox"/> Statement verifying identity of above copies</li> </ul>	
3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) <div style="float: right;">Total Sheets</div>		<b>ACCOMPANYING APPLICATION PAPERS</b>	
4. <input checked="" type="checkbox"/> Oath or Declaration <div style="float: right;">Total Pages 4</div> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Newly executed (original or copy)</li> <li>b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d))  <small>(for continuation/divisional with Box 17 completed)</small> <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b>            Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33 (b)</li> </ul> </li> </ul>		8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 9. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement <small>(when there is an assignee)</small> <input checked="" type="checkbox"/> Power of Attorney 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input checked="" type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 14. <input type="checkbox"/> *Small Entity Statement(s) (PTO/SB/09-12) <input type="checkbox"/> Statement filed in prior application, Status is proper and desired 15. <input type="checkbox"/> Certified Copy of Priority Document(s) 16. <input type="checkbox"/> Other:	
5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be a part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		<b>* NOTE FOR ITEMS 1 &amp; 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)</b>	
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP) of prior application No: 09/061,709 filed April 17, 1998 Prior application information: Examiner: NOT ASSIGNED Group / Art Unit: NOT ASSIGNED			
<b>18. CORRESPONDENCE ADDRESS</b>			
<input type="checkbox"/> Customer Number or bar code label (Insert Customer No. or Attach bar code label here) or <input type="checkbox"/> Correspondence address below			
Name FULBRIGHT & JAWORSKI LLP Address 666 FIFTH AVENUE City NEW YORK State NEW YORK ZIP Code 10103 Country USA Telephone 212-318-3000 Fax 212-752-5958			
Name (Print/Type) NORMAN D. HANSON		Registration No. (Attorney/Agent) 30,946	
Signature <i>[Signature]</i>		Date 3/16/1999	

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : CHEN et al..  
Serial No. : Assigned Herewith  
Filing Date : Concurrently  
For : ISOLATED NUCLEIC ACID MOLECULE ENCODING CANCER  
ASSOCIATED ANTIGENS, THE ANTIGENS PER SE, AND USES  
THEREOF  
Art Unit :  
Examiner :

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

March 16, 1999

**PRELIMINARY AMENDMENT**

S I R:

Prior to examination, please amend this application as follows:

**IN THE CLAIMS**

Cancel claims 1-52 without prejudice.


**REMARKS**

Claims 53-109 will be pending. Claims 1-52 are pending in the parent application, so they are cancelled.

Respectfully submitted,

**FULBRIGHT & JAWORSKI L.L.P.**

By

  
Norman D. Hanson  
Reg. No. 30,946

666 Fifth Avenue  
New York, New York 10103  
(212) 318-3000

LUD 5538.1-JEL/NDH

ISOLATED NUCLEIC ACID MOLECULE ENCODING  
CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE,  
AND USES THEREOF

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224

## RELATED APPLICATION

This application is a continuation in part of Serial No. 09/061,709 filed April 17, 1998, incorporated by reference.

## FIELD OF THE INVENTION

This invention relates to antigens associated with cancer, the nucleic acid molecules encoding them, as well as the uses of these.

## BACKGROUND AND PRIOR ART

It is fairly well established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc., are characterized by the inappropriate expression of certain molecules. These molecules thus serve as "markers" for a particular pathological or abnormal condition. Apart from their use as diagnostic "targets", i.e., materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents. A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker. Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells.

Preparation of such materials, of course, presupposes a source of the reagents used to generate these. Purification from cells is one laborious, far from sure method of doing so. Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule.

Two basic strategies have been employed for the detection of such antigens, in e.g., human tumors. These will be referred to as the genetic approach and the biochemical approach. The genetic approach is exemplified by, e.g., dePlaen et al., Proc. Natl. Sci. USA 85: 2275

(1988), incorporated by reference. In this approach, several hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negative variants of tumor cell lines which are tested for the expression of the specific antigen. The biochemical approach, exemplified by, e.g., O. Mandelboim, et al., *Nature* 369: 69 (1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromatography (HPLC). Antigenic peptides are identified after they bind to empty MHC-class I molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytotoxic T-lymphocytes. These reactions include induction of CTL proliferation, TNF release, and lysis of target cells, measurable in an MTT assay, or a  $^{51}\text{Cr}$  release assay.

These two approaches to the molecular definition of antigens have the following disadvantages: first, they are enormously cumbersome, time-consuming and expensive; and second, they depend on the establishment of cytotoxic T cell lines (CTLs) with predefined specificity.

The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods have, so far, succeeded in defining only very few new antigens in human tumors. See, e.g., van der Bruggen et al., *Science* 254: 1643-1647 (1991); Brichard et al., *J. Exp. Med.* 178: 489-495 (1993); Coulie, et al., *J. Exp. Med.* 180: 35-42 (1994); Kawakami, et al., *Proc. Natl. Acad. Sci. USA* 91: 3515-3519 (1994).

Further, the methodologies described rely on the availability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by, e.g., Oettgen, et al., *Immunol. Allerg. Clin. North. Am.*

10: 607-637 (1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs in vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens.

One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. Patent No. 5,698,396, and Application Serial No. 08/479,328, filed on June 7, 1995 and January 3, 1996, respectively. All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immunoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method ("Serological identification of antigens by Recombinant Expression Cloning"). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144: 2333-2340 (1995).

This methodology has been applied to a range of tumor types, including those described by Sahin et al., supra, and Pfreundschuh, supra, as well as to esophageal cancer (Chen et al., Proc. Natl. Acad. Sci. USA 94: 1914-1918 (1997)); lung cancer (Güre et al., Cancer Res. 58: 1034-1041 (1998)); colon cancer (Serial No. 08/948, 705 filed October 10, 1997) incorporated by reference, and so forth. Among the antigens identified via SEREX are the SSX2 molecule (Sahin et al., Proc. Natl. Acad. Sci. USA 92: 11810-11813 (1995); Tureci et al., Cancer Res. 56: 4766-4772 (1996); NY-ESO-1 Chen, et al., Proc. Natl. Acad. Sci. USA 94: 1914-1918 (1997); and SCP1 (Serial No. 08/892,705 filed July 15, 1997) incorporated by reference.

Analysis of SEREX identified antigens has shown overlap between SEREX defined and CTL defined antigens. MAGE-1, tyrosinase, and NY-ESO-1 have all been shown to be recognized by patient antibodies as well as CTLs, showing that humoral and cell mediated responses do act in concert.

It is clear from this summary that identification of relevant antigens via SEREX is a desirable aim. The inventors have modified standard SEREX protocols and have screened a cell line known to be a good source of the antigens listed supra, using allogeneic patient sample. New antigens have been identified in this way and have been studied. Also, a previously known molecule has now been identified via SEREX techniques.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

##### Example 1

The melanoma cell referred to as SK-MEL-37 was used, because it has been shown to express a number of members of the CT antigen family, including MAGE-1 (Chen et al., Proc. Natl. Acad. Sci. USA 91: 1004-1008 (1994); NY-ESO-1 (Chen et al. Proc. Natl. Acad. Sci. USA 94: 1914-1918 (1997)); and various members of the SSX family (Gure et al., Int. J. Cancer 72: 965-971 (1997)).

Total RNA was extracted from cultured samples of SK-MEL-37 using standard methods, and this was then used to construct a cDNA library in commercially available,  $\lambda$ ZAP expression vector, following protocols provided by the manufacturer. The cDNA was then transfected into E. coli and screened, following Sahin et al., Proc. Natl. Acad. Sci. USA 92: 11810-11813 (1995), incorporated by reference, and Pfreundschuh, U.S. Patent No. 5,698,396, also incorporated by reference. The screening was done with allogeneic patient serum "NW38." This serum had been shown, previously, to contain high titer antibodies against MAGE-1 and NY-

ESO-1. See, e.g., Jäger et al., J. Exp. Med. 187: 265-270 (1998), incorporated by reference.

In brief, serum was diluted 1:10, preabsorbed with lysates of transfected E. coli, further diluted to 1:2000, and then incubated overnight at room temperature with nitrocellulose membranes containing phage plaques, prepared in accordance with Sahin et al., and Pfreundschuh, supra. The library contained a total of  $2.3 \times 10^7$  primary clones. After washing, the filters were incubated with alkaline phosphatase conjugated, goat anti-human Fc $\gamma$  secondary antibodies, and were then visualized by incubating with 5-bromo-4-chloro-3-indolyl phosphate, and nitroblue tetrazolium.

After screening  $1.5 \times 10^5$  of the clones, a total of sixty-one positives had been identified. Given this number, screening was stopped, and the positive clones were subjected to further analysis.

### Example 2

The positive clones identified in example 1, supra, were purified, the inserts were excised in vitro, and inserted into a commercially available plasmid, pBK-CMV, and then evaluated on the basis of restriction mapping with EcoRI and XbaI. Clones which represented different inserts on the basis of this step were sequenced, using standard methodologies.

There was a group of 10 clones, which could not be classified other than as “miscellaneous genes”, in that they did not seem to belong to any particular family. They consisted of 9 distinct genes, of which four were known, and five were new. The fifty one remaining clones were classified into four groups. The data are presented in Tables 1 and 2, which follow.

The largest group are genes related to KOC (“KH-domain containing gene, overexpressed in cancer” which has been shown to be overexpressed in pancreatic cancer, and maps to



chromosome 7p11.5. See Müller-Pillasch et al., *Oncogene* 14: 2729-2733 (1997). Two of the 33 were derived from the KOC gene, and the other 31 were derived from two previously unidentified, but related genes. Examples 6 et seq. describe work on this group of clones.

Eleven clones, i.e., Group 2, were MAGE sequences. Four were derived from MAGE-4a, taught by DePlaen et al., *Immunogenetics* 40: 360-369, Genbank U10687, while the other 7 hybridized to a MAGE-4a probe, derived from the 5' sequence, suggesting they belong to the MAGE family.

The third group consisted of five clones of the NY-ESO-1 family. Two were identical to the gene described by Chen et al., *Proc. Natl. Acad. Sci. USA* 94: 1914-1918 (1997), and in Serial No. 08/725,182, filed October 3, 1996, incorporated by reference. The other three were derived from a second member of the NY-ESO-1 family, i.e., LAGE-1. See U.S. application Serial No. 08/791,495, filed January 27, 1997 and incorporated by reference.

The fourth, and final group, related to a novel gene referred to as CT7. This gene, the sequence of which is presented as SEQ ID NO: 1, was studied further.

Table 1. SEREX-identified genes from allogeneic screening of SK-MEL-37 library

Gene group	# of clones	Comments
KOC	33	derived from 3 related genes
MAGE	11	predominantly MAGE-4a (see text)
NY-ESO-1	5	derived from 2 related genes (NY-ESO-1, LAGE-1)
CT7	2	new cancer/testis antigen
Miscellaneous	10	see Table 2

Table 2. SEREX-identified genes from allogeneic screening of SK-MEL-37 library--  
Miscellaneous group

Clone designation	Gene
MNW-4, MNW-7	S-adenyl homocysteine hydrolase
MNE-6a	Glutathione synthetase
MNW-24	proliferation-associated protein p38-2G4
MNW-27a	phosphoribosyl pyrophosphate synthetase-associated protein 39
MNW-6b	unknown gene, identical to sequence tags from pancreas, uterus etc.
MNW-14b	unknown gene, identical to sequence tags from lung, brain, fibroblast etc.
MNW-34a	unknown gene, identical to sequence tags from multiple tissues
MNW-17	unknown gene, identical to sequence tags from pancreas and fetus
MNW-29a	unknown gene, no significant sequence homology, universally expressed

Example 3

The two clones for CT7, referred to supra, were 2184 and 1965 base pairs long. Analysis of the longer one was carried out. It presented an open reading frame of 543 amino acids, which extended to the 5' end of the sequence, indicating that it was a partial cDNA clone.

In order to identify the complete sequence, and to try to identify additional, related genes, a human testicular cDNA library was prepared, following standard methods, and screened with probes derived from the longer sequence, following standard methods.

Eleven positives were detected, and sequenced, and it was found that all derived from the same gene. When the polyA tail was excluded, full length transcript, as per SEQ ID NO: 1, consisted of 4265 nucleotides, broken down into 286 base pairs of untranslated 5' - region, a coding region of 3429 base pairs, and 550 base pairs of untranslated 3' region. The predicted protein is 1142 amino acids long, and has a calculated molecular mass of about 125 kilodaltons. See SEQ ID NO: 2.

The nucleotide and deduced amino acid sequences were screened against known databases, and there was some homology with the MAGE-10 gene, described by DePlaen et al., Immunogenetics 40: 360-369 (1994). The homology was limited to about 210 carboxy terminal amino acids, i.e., amino acids 908-1115 of the subject sequence, and 134-342 of MAGE-10. The percent homology was 56%, rising to 75% when conservative changes are included.

There was also extensive homology with a sequence reported by Lucas et al., Canc. Res. 58: 743-752 (1998), and application Serial No. 08/845,528 filed April 25, 1997, also incorporated by reference. A total of 14 nucleotides differ in the open reading frame, resulting in a total of 11 amino acids which differ between the sequences.

The 5' region of the nucleotide and sequence and corresponding amino acid sequence demonstrates a strikingly repetitive pattern, with repeats rich in serine, proline, glutamine, and leucine, with an almost invariable core of PQSPLQI (SEQ ID NO: 3). In the middle of the molecule, 11 almost exact repeats of 35 amino acids were observed. The repetitive portions make up about 70% of the entire sequence, begin shortly after translation initiation, at position 15, and ending shortly before the region homologous to MAGE 4a.

#### Example 4

The expression pattern for mRNA of CT7 was then studied, in both normal and malignant tissues. RT-PCR was used, employing primers specific for the gene. The estimated melting temperature of the primers was 65-70°C, and they were designed to amplify 300-600 base pair segments. A total of 35 amplification cycles were carried out, at an annealing temperature of 60°C. Table 3, which follows, presents the data for human tumor tissues. CT7 was expressed in a number of different samples. Of fourteen normal tissues tested, there was strong expression in testis, and none in colon, brain, adrenal, lung, breast, pancreas, prostate, thymus or uterus tissue. There was low level expression in liver, kidney, placenta and fetal brain, with fetal brain showing three transcripts of different size. The level of expression was at least 20-50 times lower than in testis. Melanoma cell lines were also screened. Of these 7 of the 12 tested showed strong expression, and one showed weak expression.

Table 3. CT7 mRNA expression in various humor tumors by RT-PCR

Tumor type	mRNA, positive/total
Melanoma	7/10
Breast cancer	3/10
Lung cancer	3/9
Head/neck cancer	5/14
Bladder cancer	4/9
Colon cancer	1/10
Leiomyosarcoma	1/4
synovial sarcoma	2/4
Total	26/70

#### Example 5

Southern blotting experiments were then carried out to determine if CT7 belonged to a family of genes. In these experiments, genomic DNA was extracted from normal human tissues. It was digested with BamHI, EcoRI, and HindIII, separated on a 0.7% agarose gel, blotted onto a nitrocellulose filter, and hybridized, at high stringency (65°C, aqueous buffer), with a <sup>32</sup>P labelled probe, derived from SEQ ID NO: 1.

The blotting showed anywhere from two to four bands, suggesting one or two genes in the family.

#### Example 6

As noted in example 2, supra, thirty three of the sixty one positive clones were related to KOC. Clones were sequenced using standard methodologies. As indicated supra, one clone

was identical to KOC, initially reported by Müller-Pillasch, et al., supra. Given that two additional related sequences were identified, the known KOC gene is referred to as KOC-1 hereafter (SEQ ID NO: 4). The second clone, referred to as KOC-2 hereafter, was found once. The sequence is presented as SEQ ID NO: 5. Its deduced amino acid sequence is 72.5% identical to that for KOC-1.

The third sequence, KOC-3, appeared thirty times (SEQ ID NO: 6). Its deduced amino acid sequence is 63% identical to KOC-1.

Testicular cDNA libraries were analyzed in the same way that the SK-MEL-37 library was analyzed, i.e., with allogeneic serum from NW-38. See example 3, supra.

Following analysis of testicular libraries, a longer form of KOC-2 was isolated. This is presented as SEQ ID NO: 7. When SEQ ID NOS: 5 & 7 are compared, the former is 1705 base pairs in length, without a polyA tail. It contains 1362 base pairs of coding sequence, and 343 base pairs of 3' untranslated sequence. Nucleotides 275-1942 of SEQ ID NO: 7 are identical to nucleotides 38-1705 of SEQ ID NO: 5.

The sequence of KOC-3, set forth as SEQ ID NO: 6, is 3412 base pairs long, and consists of 72 base pairs of 5' untranslated region, 1707 base pairs of open reading frame, and 1543 base pairs of untranslated, 3' region. An alternate form was also isolated, (SEQ ID NO: 8), and is 129 base pairs shorter than SEQ ID NO: 6.

#### Example 7

Expression patterns for KOC-1, KOC-2 and KOC-3 were then studied, using RT-PCR and the following primer pairs:

GAAAGTATCT TCAAGGACGC C

CTGCAAGGGG TTTTGCTGGG CG

(SEQ ID NOS: 9 & 10).

TCCTTGCGCG CTGCGGCCTC AG

CCAACTGGTG GCCATTAGCT TC

(SEQ ID NOS: 11 & 12)

GCTCTTTGGG GACAGGAAGG TC

GACGTTGACA ACGGCGGTTT CT

(SEQ ID NOS: 13 & 14).

SEQ ID NOS: 9 & 10 were designed to amplify KOC-1 while SEQ ID NOS: 11 & 12 were designed to amplify KOC-2, and SEQ ID NOS: 13 & 14 were designed to amplify KOC-3.

To carry out the RT-PCR, relevant primer pairs were added to cDNA samples prepared from various mRNAs by reverse transcription. PCR was then carried out at an annealing temperature of 60°C, and extension at 72°C, for 35 cycles. The resulting products were then analyzed by gel electrophoresis.

SEQ ID NOS 9 & 10 amplify nucleotides 305-748 of SEQ ID NO: 1. A variety of normal and malignant cell types were tested. Strong expression was found in testis, moderate expression in normal brain, and low levels of expression were found in normal colon, kidney, and liver.

The Müller-Pillasch paper, cited supra, identified expression of KOC-1 in pancreatic tumor cell lines, gastric cancer, and normal placenta, via Northern blotting. This paper also reported that normal heart, brain, lung, liver, kidney and pancreatic tissue were negative for

KOC-1 expression. The difference in results suggests that the level of expression of KOC-1 is very low in normal tissues.

When KOC-2 expression was studied, the only positive normal tissue was testis (brain, liver, kidney and colon were negative).

Modification of the protocol for detecting KOC-2 resulted in positives in normal kidney, liver and melanoma.

When KOC-3 expression was studied, it was found that the gene was universally expressed in normal tissues, with highest expression in testis.

The pattern of expression of KOC-3 in different melanoma cell lines was analyzed, using standard Northern blotting. Over expression in several cell lines was observed, which is consistent with the more frequent isolation of this clone than any other.

### Example 8

A study was carried out to determine if KOC-1 is expressed at higher levels in melanoma cells, as compared to normal skin cells. This was done using representational difference analysis, or "RDA." See Lisitsyn, et al. Science 259: 946-951 (1993), and O'Neill, et al. Nucl. Acids Res. 25:2681-2 (1997), both of which are incorporated by reference. Specifically, tester cDNA was taken from SK-MEL-37, and driver cDNA was taken from a skin sample representing mRNA from various cell types in the skin. The cDNAs were digested with either Tsp509I, Hsp92II, or DpnII. When DpnII was the enzyme used for digestion, adaptor oligonucleotides R-Bgl-24, J-Bgl-24, and N-Bgl-24 described by O'Neill, et al., supra, and Hubank, et al. Nucl. Acids Res.



22:5640-5648 (1994) were used. When Tsp509I was the endonuclease, the same adaptors were used, as were R-Tsp-12, i.e.:

AATTGCGGT GA

(SEQ ID NO: 15)

J-Tsp-12, i.e.:

AATTGTGTTCA TG

(SEQ ID NO: 16)

and N-Tsp-12, i.e.:

AATTTTCCT CG

(SEQ ID NO: 17)

When Hsp92II was the endonuclease, the adaptors were:

R-Hsp-24, i.e.:

AGCACTCTCC AGCCTCTCAC CATG

(SEQ ID NO: 18);

J-Hsp-24, i.e.:

ACCGACGTCG ACTATCATG CATG

(SEQ ID NO: 19);

N-Hsp-24, i.e.:

AGGCAACTGT GCTATCCGAG CATG

(SEQ ID NO: 20);

R-Hsp-8, i.e.:

GTGAGAGG

(SEQ ID NO: 21);

J-Hsp-8, i.e.:

CATGGATG

(SEQ ID NO: 22);

N-Hsp-8, i.e.:

CTCGGATA

(SEQ ID NO: 23).

In order to hybridize tester and driver, either 3XEE buffer (30mM EPPS, pH8, 3mM EDTA), or a buffer of 2.4M tetraethylammonium chloride (TEACl) 3mM EDTA, 10mM Tris HCl, pH8, was used. When DNA was dissolved in 10  $\mu$ l of TEACl buffer, it was denatured at 80°C for 10 minutes, followed by renaturing at 42°C for 20 hours. Amplicons were gel purified, and the DP3 or DP2 product was ligated into BamHI (when DpnII was used), EcoRI (when Tsp 509I was used), or SphI (when Hsp92II was used), cloning vectors were digested, and then sequenced. Sequence analysis of the cDNA molecules derived from these experiments identified KOC-1 as one of the genes isolated, indicating that KOC-1 mRNA is present at a higher level in Sk-Mel 37 cells as compared to normal skin cells.

The foregoing examples describe the isolation of a nucleic acid molecule which encodes a cancer associated antigen. "Associated" is used herein because while it is clear that the relevant molecule was expressed by several types of cancer, other cancers, not screened herein, may also express the antigen.

The invention relates to those nucleic acid molecules which encode the antigens CT7, KOC-2 and KOC-3, as described herein, such as a nucleic acid molecule consisting of the nucleotide sequence SEQ ID NO: 1, molecules comprising the nucleotide sequence of SEQ ID

NO: 5, 6, 7 or 8 and so forth. Also embraced are those molecules which are not identical to SEQ ID NOS: 1, 5, 6, 7 or 8, but which encode the same antigen.

Also a part of the invention are expression vectors which incorporate the nucleic acid molecules of the invention, in operable linkage (i.e., "operably linked") to a promoter. Construction of such vectors, such as viral (e.g., adenovirus or Vaccinia virus) or attenuated viral vectors is well within the skill of the art, as is the transformation or transfection of cells, to produce eukaryotic cell lines, or prokaryotic cell strains which encode the molecule of interest. Exemplary of the host cells which can be employed in this fashion are COS cells, CHO cells, yeast cells, insect cells (e.g., Spodoptera frugiperda), NIH 3T3 cells, and so forth. Prokaryotic cells, such as E. coli and other bacteria may also be used. Any of these cells can also be transformed or transfected with further nucleic acid molecules, such as those encoding cytokines, e.g., interleukins such as IL-2, 4, 6, or 12 or HLA or MHC molecules.

Also a part of the invention are the antigens described herein, both in original form and in any different post translational modified forms. The molecules are large enough to be antigenic without any posttranslational modification, and hence are useful as immunogens, when combined with an adjuvant (or without it), in both precursor and post-translationally modified forms. Antibodies produced using these antigens, both poly and monoclonal, are also a part of the invention as well as hybridomas which make monoclonal antibodies to the antigens. The whole protein can be used therapeutically, or in portions, as discussed infra. Also a part of the invention are antibodies against this antigen, be these polyclonal, monoclonal, reactive fragments, such as Fab, (F(ab)<sub>2</sub>' and other fragments, as well as chimeras, humanized antibodies, recombinantly produced antibodies, and so forth.

As is clear from the disclosure, one may use the proteins and nucleic acid molecules of the invention diagnostically. The SEREX methodology discussed herein is premised on an immune response to a pathology associated antigen. Hence, one may assay for the relevant pathology via, e.g., testing a body fluid sample of a subject, such as serum, for reactivity with the antigen *per se*. Reactivity would be deemed indicative of possible presence of the pathology. So, too, could one assay for the expression of any of the antigens via any of the standard nucleic acid hybridization assays which are well known to the art, and need not be elaborated upon herein. One could assay for antibodies against the subject molecules, using standard immunoassays as well.

Analysis of SEQ ID NO: 1, 5, 6, 7 and 8 will show that there are 5' and 3' non-coding regions presented therein. The invention relates to those isolated nucleic acid molecules which contain at least the coding segment, i.e., nucleotides 54-593, of SEQ ID NO: 1, nucleotides 1-1019 of SEQ ID NO: 3, nucleotides 73-1780 of SEQ ID NO: 8, and so forth, and which may contain any or all of the non-coding 5' and 3' portions.

Also a part of the invention are portions of the relevant nucleic acid molecules which can be used, for example, as oligonucleotide primers and/or probes, such as one or more of SEQ ID NOS: 7, 8, 9, 10, 11, 12, 13 or 14 as well as amplification product like nucleic acid molecules comprising at least nucleotides 305-748 of SEQ ID NO: 1.

As was discussed supra, study of other members of the "CT" family reveals that these are also processed to peptides which provoke lysis by cytolytic T cells. There has been a great deal of work on motifs for various MHC or HLA molecules, which is applicable here. Hence, a further aspect of the invention is a therapeutic method, wherein one or more peptides derived

from the antigens of the invention which bind to an HLA molecule on the surface of a patient's tumor cells are administered to the patient, in an amount sufficient for the peptides to bind to the MHC/HLA molecules, and provoke lysis by T cells. Any combination of peptides may be used. These peptides, which may be used alone or in combination, as well as the entire protein or immunoreactive portions thereof, may be administered to a subject in need thereof, using any of the standard types of administration, such as intravenous, intradermal, subcutaneous, oral, rectal, and transdermal administration. Standard pharmaceutical carriers, adjuvants, such as saponins, GM-CSF, and interleukins and so forth may also be used. Further, these peptides and proteins may be formulated into vaccines with the listed material, as may dendritic cells, or other cells which present relevant MHC/peptide complexes.

Similarly, the invention contemplates therapies wherein nucleic acid molecules which encode the proteins of the invention, one or more or peptides which are derived from these proteins are incorporated into a vector, such as a Vaccinia or adenovirus based vector, to render it transfectable into eukaryotic cells, such as human cells. Similarly, nucleic acid molecules which encode one or more of the peptides may be incorporated into these vectors, which are then the major constituent of nucleic acid bases therapies.

Any of these assays can also be used in progression/regression studies. One can monitor the course of abnormality involving expression of these antigens simply by monitoring levels of the protein, its expression, antibodies against it and so forth using any or all of the methods set forth supra.

It should be clear that these methodologies may also be used to track the efficacy of a therapeutic regime. Essentially, one can take a baseline value for a protein of interest using any

of the assays discussed supra, administer a given therapeutic agent, and then monitor levels of the protein thereafter, observing changes in antigen levels as indicia of the efficacy of the regime.

As was indicated supra, the invention involves, inter alia, the recognition of an "integrated" immune response to the molecules of the invention. One ramification of this is the ability to monitor the course of cancer therapy. In this method, which is a part of the invention, a subject in need of the therapy receives a vaccination of a type described herein. Such a vaccination results, e.g., in a T cell response against cells presenting HLA/peptide complexes on their cells. The response also includes an antibody response, possibly a result of the release of antibody provoking proteins via the lysis of cells by the T cells. Hence, one can monitor the effect of a vaccine, by monitoring an antibody response. As is indicated, supra, an increase in antibody titer may be taken as an indicia of progress with a vaccine, and vice versa. Hence, a further aspect of the invention is a method for monitoring efficacy of a vaccine, following administration thereof, by determining levels of antibodies in the subject which are specific for the vaccine itself, or a large molecule of which the vaccine is a part.

The identification of the subject proteins as being implicated in pathological conditions such as cancer also suggests a number of therapeutic approaches in addition to those discussed supra. The experiments set forth supra establish that antibodies are produced in response to expression of the protein. Hence, a further embodiment of the invention is the treatment of conditions which are characterized by aberrant or abnormal levels of one or more of the proteins, via administration of antibodies, such as humanized antibodies, antibody fragments, and so forth. These may be tagged or labelled with appropriate cystostatic or cytotoxic reagents.

T cells may also be administered. It is to be noted that the T cells may be elicited in vitro using immune responsive cells such as dendritic cells, lymphocytes, or any other immune responsive cells, and then reperfused into the subject being treated.

Note that the generation of T cells and/or antibodies can also be accomplished by administering cells, preferably treated to be rendered non-proliferative, which present relevant T cell or B cell epitopes for response, such as the epitopes discussed supra.

The therapeutic approaches may also include antisense therapies, wherein an antisense molecule, preferably from 10 to 100 nucleotides in length, is administered to the subject either "neat" or in a carrier, such as a liposome, to facilitate incorporation into a cell, followed by inhibition of expression of the protein. Such antisense sequences may also be incorporated into appropriate vaccines, such as in viral vectors (e.g., Vaccinia), bacterial constructs, such as variants of the known BCG vaccine, and so forth.

Also a part of the inventions are Peptides, such as those set forth in Figure 1, and those which have as a core sequence

PQSPLQI (SEQ ID NO.: 3)

These peptides may be used therapeutically, via administration to a patient who expresses CT7 in connection with a pathology, as well as diagnostically, i.e., to determine if relevant antibodies are present and so forth.

Other features and applications of the invention will be clear to the skilled artisan, and need not be set forth herein. The terms and expression which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expression of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

We claim:

1. Isolated nucleic acid molecule which encodes a cancer associated antigen, whose amino acid sequence is identical to the amino sequence encoded by nucleotides 287 to 3714 of SEQ ID NO: 1.
2. The isolated nucleic acid molecule of claim 1, consisting of nucleotides 287-3714 of SEQ ID NO: 1.
3. The isolated nucleic acid molecule of claim 1, consisting of anywhere from nucleotide 1 through nucleotide 4265 of SEQ ID NO: 1, with the proviso that said isolated nucleic acid molecule contains at least nucleotides 287-3714 of SEQ ID NO: 1.
4. Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.
5. Expression vector comprising the isolated nucleic acid molecule of claim 3, operably linked to a promoter.
6. Eukaryotic cell line or prokaryotic cell strain, transformed or transfected with the expression vector of claim 4.
7. Eukaryotic cell line or prokaryotic cell strain, transformed or transfected with the expression vector of claim 5.
8. Isolated cancer associated antigen comprising all or part of the amino acid sequence encoded by nucleotides 287-3714 of SEQ ID NO: 1.
9. Eukaryotic cell line or prokaryote cell strain, transformed or transfected with the isolated nucleic acid molecule of claim 1.
10. The eukaryotic cell line of claim 9, wherein said cell line is also transfected with a nucleic acid molecule coding for a cytokine.



11. The eukaryotic cell line of claim 10, wherein said cell line is further transfected by a nucleic acid molecule coding for an HLA molecule.
12. The eukaryotic cell line of claim 10, wherein said cytokine is an interleukin.
13. The biologically pure culture of claim 12, wherein said interleukin is IL-2, IL-4 or IL-12.
14. The eukaryotic cell line of claim 9, wherein said cell line has been rendered non-proliferative.
15. The eukaryotic cell line of claim 9, wherein said cell line is a fibroblast cell line.
16. Expression vector comprising a mutated or attenuated virus and the isolated nucleic acid molecule of claim 1.
17. The expression vector of claim 16, wherein said virus is adenovirus or vaccinia virus.
18. The expression vector of claim 17, wherein said virus is vaccinia virus.
19. The expression vector of claim 17, wherein said virus is adenovirus.
20. Expression system useful in transfecting a cell, comprising (i) a first vector containing a nucleic acid molecule which codes for the isolated cancer associated antigen of claim 8 and (ii) a second vector selected from the group consisting of (a) a vector containing a nucleic acid molecule which codes for an MHC or HLA molecule which presents an antigen derived from said cancer associated antigen and (b) a vector containing a nucleic acid molecule which codes for an interleukin.
21. Isolated cancer associated antigen comprising the amino acid sequence encoded by nucleotides 287-3714 of SEQ ID NO: 1.

22. Immunogenic composition comprising the isolated antigen of claim 21, and a pharmaceutically acceptable adjuvant.

23. The immunogenic composition of claim 22, wherein said adjuvant is a cytokine, a saponin, or GM-CSF.

24. Immunogenic composition comprising at least one peptide consisting of an amino acid sequence of from 8 to 12 amino acids concatenated to each other in the isolated cancer associated antigen of claim 21, and a pharmaceutically acceptable adjuvant.

25. The immunogenic composition of claim 24, wherein said adjuvant is a saponin, a cytokine, or GM-CSF.

26. The immunogenic composition of claim 24, wherein said composition comprises a plurality of peptides which complex with a specific MHC molecule.

27. Isolated peptide derived from the amino acid sequence encoded by SEQ ID NO: 1, wherein said isolated peptide binds to an HLA molecule, is a nonamer, decamer or undecamer, and comprises the amino acid sequence of SEQ ID NO: 3, from one to three additional N-terminal amino acid, and up to four additional C terminal amino acids.

28. Immunogenic composition which comprises at least one expression vector which encodes for a peptide derived from the amino acid sequence encoded by SEQ ID NO: 1, and an adjuvant or carrier.

29. The immunogenic composition of claim 28, wherein said at least one expression vector codes for a plurality of peptides.

30. Vaccine useful in treating a subject afflicted with a cancerous condition comprising the isolated cell line of claim 11 and a pharmacologically acceptable adjuvant.

31. The vaccine of claim 30, wherein said cell line has been rendered non-proliferative.
32. The vaccine of claim 31, wherein said cell line is a human cell line.
33. A composition of matter useful in treating a cancerous condition comprising a non proliferative cell line having expressed on its surface a peptide derived from the amino acid sequence encoded by SEQ ID NO: 1.
34. The composition of matter of claim 33, wherein said cell line is a human cell line.
35. A composition of matter useful in treating a cancerous condition, comprising (i) a peptide derived from the amino acid sequence encoded by SEQ ID NO: 1, (ii) an MHC or HLA molecule, and (iii) a pharmaceutically acceptable carrier.
36. Isolated antibody which is specific for the antigen of claim 21.
37. The isolated antibody of claim 36, wherein said antibody is a monoclonal antibody.
38. Method for screening for cancer in a sample, comprising contacting said sample with a nucleic acid molecule which hybridizes to all or part of SEQ ID NO: 1, and determining hybridization as an indication of cancer cells in said sample.
39. A method for screening for cancer in a sample, comprising contacting said sample with the isolated antibody of claim 36, and determining binding of said antibody to a target as an indicator of cancer.
40. Method for diagnosing a cancerous condition in a subject, comprising contacting an immune reactive cell containing sample of said subject to a cell line transfected with the isolated nucleic acid molecule of claim 1, and determining interaction of said transfected cell line with said immunoreactive cell, said interaction being indicative of said cancer condition.

41. A method for determining regression, progression of onset of a cancerous condition comprising monitoring a sample from a patient with said cancerous condition for a parameter selected from the group consisting of (i) CT7 protein, (ii) a peptide derived from CT7 protein (iii) cytolytic T cells specific for said peptide and an MHC molecule with which it non-covalently complexes, and (iv) antibodies specific for said CT7 protein, wherein amount of said parameter is indicative of progression or regression or onset of said cancerous condition.

42. Method of claim 41, wherein said sample is a body fluid or exudate.

43. Method of claim 41, wherein said sample is a tissue.

44. Method of claim 41, comprising contacting said sample with an antibody which specifically binds with said protein or peptide.

45. Method of claim 44, wherein said antibody is labelled with a radioactive label or an enzyme.

46. Method of claim 44, wherein said antibody is a monoclonal antibody.

47. Method of claim 41, comprising amplifying RNA which codes for said protein.

48. Method of claim 47, wherein said amplifying comprises carrying out polymerase chain reaction.

49. Method of claim 41, comprising contacting said sample with a nucleic acid molecule which specifically hybridizes to a nucleic acid molecule which codes for or expresses said protein.

50. Method of claim 41, comprising assaying said sample for shed protein.

51. Method of claim 41, comprising assaying said sample for antibodies specific for said CT7 protein, by contacting said sample with CT7 protein.

52. Method for diagnosing a cancerous condition comprising assaying a sample taken from a subject for an immunoreactive cell specific for a peptide derived from CT7, complexed to an MHC molecule, presence of said immunoreactive cell being indicative of said cancerous condition.

53. An isolated nucleic acid molecule which encodes a protein and which has a complementary sequence which hybridizes, under stringent conditions, to at least one of the nucleotide sequences set forth at SEQ ID NO: 5, 6, 7 or 8.

54. The isolated nucleic acid molecule of claim 53, wherein said protein is the protein encoded by the nucleotide sequence of SEQ ID NO: 5, 6, 7 or 8.

55. The isolated nucleic acid molecule of claim 53, selected from the group consisting of nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 5, 6, 7 or 8.

56. Expression vector comprising the isolated nucleic acid molecule of claim 54, operably linked to a promoter.

57. Expression vector comprising the isolated nucleic acid molecule of claim 55, operably linked to a promoter.

58. Recombinant cell comprising the expression vector of claim 56.

59. Recombinant cell comprising the expression vector of claim 57.

60. Recombinant cell comprising the isolated nucleic acid molecule of claim 54.

61. Recombinant cell comprising the isolated nucleic acid molecule of claim 55.

62. Recombinant cell of claim 58, further comprising an expression vector which contains a nucleic acid molecule encoding a cytokine, operably linked to a promoter.

63. Recombinant cell of claim 59, further comprising an expression vector which contains a nucleic acid molecule encoding a cytokine, operably linked to a promoter.

64. Recombinant cell of claim 60, further comprising a nucleic acid molecule which encodes a cytokine.

65. Recombinant cell of claim 61, further comprising a nucleic acid molecule which encodes a cytokine.

66. The recombinant cell of claim 62, 63, 64, or 65, wherein said cytokine is interleukin.

67. The recombinant cell of claim 66, wherein said interleukin is 1L-2, 1L-4, or 1L-12.

68. The recombinant cell of claim 58, 59, 60, or 61, wherein said recombinant cell is a eukaryotic cell.

69. The recombinant cell of claim 68, which has been rendered non-proliferative.

70. The recombinant cell of claim 68, wherein said cell is a fibroblast.

71. Expression vector comprising a mutated or attenuated virus and the isolated nucleic acid molecule of claim 53, 54 or 55.

72. The expression vector of claim 71, wherein said virus is adenovirus, adeno associated virus, or vaccinia virus.

73. Expression system useful in making a recombinant cell, comprising:

(i) a first vector which encodes the protein encoded by the isolated nucleic acid molecule of claim 53, 54 or 55, and

(ii) a second vector which either (a) encodes an MHC or HLA molecule or (b) encodes an interleukin.

74. An isolated cancer associated antigen comprising the amino acid sequence encoded by SEQ ID NO: 5, 6, 7 or 8.

75. Composition comprising the isolated cancer associated antigen of claim 74, and a pharmaceutically acceptable adjuvant.

76. The composition of claim 75, wherein said adjuvant is a cytokine, a saponin, or GM-CSF.

77. Composition comprising at least one peptide consisting of an amino acid sequence of from 8 to 25 amino acids concatenated to each other in the isolated cancer associated antigen of claim 74, and a pharmaceutically acceptable adjuvant.

78. The composition of claim 77, wherein said adjuvant is a saponin, a cytokine, or GM-CSF.

79. The composition of claim 77, comprising a plurality of MHC binding peptides.

80. Composition comprising an expression vector which encodes at least one peptide consisting of an amino acid sequence of from 8 to 25 amino acids concatenated to each other in the isolated cancer associated antigen of claim 74, and pharmaceutically acceptable adjuvant.

81. The composition of claim 80, wherein said expression vector encodes a plurality of peptides.

82. Composition useful in treating a subject afflicted with a cancer, comprising the recombinant cell of claim 69 and a pharmacologically acceptable adjuvant.

83. The composition of claim 82, wherein said recombinant cell expresses an HLA or MHC molecule.

84. The composition of claim 82, wherein said recombinant cell is a human cell.

85. The composition of claim 77, further comprising at least one MHC or HLA molecule.

86. Isolated antibody which specifically binds to the isolated cancer associated antigen of claim 74.

87. The isolated antibody of claim 86, wherein said antibody is a monoclonal antibody.

88. A method for screening for possible presence of a pathological condition, comprising assaying a sample from a patient believed to have a pathological condition for antibodies specific to at least one of the cancer associated antigens encoded by SEQ ID NOS: 4, 5, 6, 7 or 8, presence of said antibodies being indicative of possible presence of said pathological condition.

89. The method of claim 88, wherein said pathological condition is cancer.

90. The method of claim 89, wherein said cancer is melanoma.

91. The method of claim 90, further comprising contacting said sample to purified cancer associated antigen encoded by SEQ ID NO: 4, 5, 6, 7 or 8.

92. A method for screening for possible presence of a pathological condition in a subject, comprising assaying a sample taken from said subject for expression of a nucleic acid molecule, the nucleotide sequence of which comprises SEQ ID NO: 5, 6, 7 or 8, expression of said nucleic acid molecule being indicative of possible presence of said pathological condition.

93. The method of claim 92, wherein said pathological condition is cancer.

94. The method of claim 92, comprising determining expression via polymerase chain reaction.

95. The method of claim 92, comprising determining expression by contacting said sample with at least one of SEQ ID NO: 11, 12, 13 or 14.



96. A method for determining regression, progression of onset of a cancerous condition comprising monitoring a sample from a patient with said cancerous condition for a parameter selected from the group consisting of (i) a cancer associated antigen encoded by SEQ ID NO: 3, 4, 5 or 6, (ii) a peptide derived from said cancer associated antigen, (iii) cytolytic T cells specific for said peptide and an MHC molecule with which it non-covalently complexes, and (iv) antibodies specific for said cancer associated antigen, wherein amount of said parameter is indicative of progression or regression or onset of said cancerous condition.

97. The method of claim 96, wherein said sample is a body fluid or exudate.

98. The method of claim 96, wherein said sample is a tissue.

99. The method of claim 96, comprising contacting said sample with an antibody which specifically binds with said protein or peptide.

100. The method of claim 99, wherein said antibody is labelled with a radioactive label or an enzyme.

101. The method of claim 99, wherein said antibody is a monoclonal antibody.

102. The method of claim 96, comprising amplifying RNA which codes for said protein.

103. The method of claim 102, wherein said amplifying comprises carrying out polymerase chain reaction.

104. The method of claim 96, comprising contacting said sample with a nucleic acid molecule which specifically hybridizes to a nucleic acid molecule which codes for or expresses said protein.

105. The method of claim 96, comprising assaying said sample for shed cancer associated antigen.

106. The method of claim 96, comprising assaying said sample for antibodies specific for said cancer associated antigen, by contacting said sample with said cancer associated antigen.

107. Method for screening for a cancerous condition comprising assaying a sample taken from a subject for an immunoreactive cell specific for a peptide derived from a cancer associated antigen encoded by SEQ ID NO: 4, 5, 6, 7 or 8 complexed to an MHC molecule, presence of said immunoreactive cell being indicative of said cancerous condition.

108. An isolated nucleic acid molecule consisting of a nucleotide sequence defined by SEQ ID NO: 9, 10, 11, 12, 13 or 14.

109. Kit useful in determining expression of a cancer associated antigen, comprising a separate portion of each of (i) the nucleotide sequences defined by SEQ ID NOS: 9 and 10, (ii) the nucleotide sequences defined by SEQ ID NOS: 11 and 12, and (iii) the nucleotide sequences defined by SEQ ID NOS: 13 and 14.

## ABSTRACT OF THE DISCLOSURE

The invention relates to newly identified cancer associated antigens, referred to as CT7, KOC-2 and KOC-3. The invention also relates to observations regarding known molecule KOC-1. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

# SEQ ID NO: 1

GTCTGAAGGACCTGAGGCATTTTGTGACGAGGATCGTCTCAGGTGACGGGAGGGAGGACATTATAGACCTATCCAGTCT  
TCAAGGTGCTCCAGAAAGCAGGAGTTGAAGACCTGGGTGTGAGGGACACATACATCTCTAAAGCACCACAGGACGAGGAGG  
CCAGGCGAGTGCACGAGGATCAAGGTTCCAGAAAGACAAACCCCTAGGAAGACAGGGCGACCTGTGAGGGCCCTAGAGCAC  
ACCTTAAAGAGAGAAGAGCTGTAAAGCCGGCCCTTTGTGACAGGCCATCATGGGGGACAGGATATGCCCTACTGCTGGGATGTC  
CGAGTCTTCCAGAGTTCTCTTGAGAGTCCCTCAGAGTTGTCTTGAGGGGGAGGACTCCAGTCTCCCTGCCAGTTATCC  
CAGAGTTCTCCTGAGAGGCGACGACACCCCTGTATCCTCTCCAGAGTCCCTCAGAGTCTGTCGAGGGGGAGGACTCCTCGGA  
TACCTCTCCAGAGACCTCTGAGGGGGAGGACTCCAGTCTCCTCCAGAGTTCCCGAGGTTCTCCTGAGGGCGACGACA  
CCAGTCTCCTCTCCAGAAATTCAGAGTTCTCCTGAGGGGAAGGACTCCCTGTCTCTAGAGATTCTCTCAGAGCCCT  
CCTGAGGGGTGAGGATGCCAGTCTCCTCTGCAAAATCTCGAGTCTCTCTCTGCTCTGCTTTATGATATTTC  
GAGTCTCCCTGAGAGATTCAAGTCCCTTTGAGGGTTTCCCGAGTCTGTTCTCCAGATTCCTGTGAGCGCCGCCCTCTCT  
CTCCACTTTAGTGAGTATTTCCAGAGTTCCCTCGAGAGTACCAAGTCCCTTTGAGGGTTTCCCGAGTCTCCACTC

CAGATCTCTGTGAGCGCTCTCTCCACTTTATGAGTATTTCCAGAGTCCCTCGAGAGAAGTCAGAGAACTTC  
TGAGGGTTTGCACAGTCTCCTCTCCAGATTCCTGTGAGCTCCTCCTCGTCTTACTGAGCTTTCCAGAGTT  
CCCTGAGAGAACTCAGAGTACTTTTGAGGGTTTCCCGAGTCTCCACTCCAGATTCCTGTGAGCGCGCTCTCTCTCCTCC  
ACTTTATGAGTATTTCCAGAGTTCCTCCGAGAACTCAGAGTACTTTTGAGGGTTTTCGCCAGTCTCTCTCCAGAT  
TCTGTGAGGCGCCCTCTCTCCTCCACTTTAGTGAGTATTTCCAGAGTTCCTGAGAGAACTCAGAGTACTTTGAGG  
GTTTTCGCCAGTCTCCTCTCAGAGTCTCTGTGAGCTCCTCTCTCCTCCACTTTATGAGTCTTTCCAGAGTTTCCGCT  
GAGAGAACTCAGAGTACTTTTGAGGGTTTTCGCCAGTCTCCTCCAGATTCCTGTGAGCGCGCTCTCTCTCCTCCACT  
ACTGAGTCTTTTCCAGAGTCCCTCGAGAGTACCAAGTACTTTTGAGGGTTTTCGCCAGTCTCCTCTCCAGATTCCTCAG  
TCACTCTCTCTCTCTCTCTACTTTATGAGTATTTACAGAGTCTCCTGAGAGTCTCAAAAGTCTTTTGAGGGTTT  
GCCAGTCTCCTCTCAGAGTCTCTGTGAGCTCCTCTCTCTCTACTTTATGAGTCTTTCCAGAGTTCCCTGAGAG  
TCCCTCAGAGTACTTTTGAGGGTTTTCGCCAGTCTCCTCTCCAGATTCCTGTGAGCGCTCTCTCTCTCTCCTCCACT  
TGAGTCTTTCCAGAGTTCCTCGAGTACTCAAAAGTACTTTTGAGGGTTTTCGCCAGTCTCCTCTCCAGATTCCTCAG  
AGTCTCTCGAAGGGGAGAAATACCCACTCTCCTCTCCAGATTTGTCGAGTCTCTGAGTGGGAGGACTCCCTGTCTCC  
TCACTACTTTCTCAGAGCCCTCTCAGGGGGAGGACTCCCTATCTCTCACTACTTTCTCAGAGCCCTCTCAGGGGG  
AGGACTCCTGTCTCTCACTACTTTCTCAGAGCCCTCAGGGGGAGGACTCCCTGTCTCTCACTACTTTCTCAGAGCC  
CTCTCTCAGGGGGAGGACTCCATGTCTCCTCTCTACTTTCTCAGAGTCTCTCTCAGGGGGAGGAAATCCAGTCTCTCT  
CCAGAGCCCTGTGAGCATCTCTCTCTCCTCCTCACTCCATCCAGTCTTCCAGAGTTCCTCTGAGAGTCTCAGAGTCTC  
CTGAGGGGCTGTCCAGTCTCCTCTCCATAGTCTCAGAGCCCTCCTGAGGGGATGCACTCCCAATCTCCTCTCCAGAGT  
CCTGAGAGTCTCCTGAGGGGGAGGATTCCTGTCTCTCTCAAAATCTCAGAGTCTCTGAGGAGGAGGACTCCCT  
GTCCTCTCTCAATTTCTCCTCAGAGTCTCCTGAGGGGAGGACTCCCTCTCTCTCTCCTCTCCTCAGTTCCTCTCT  
AGGGGGAGGACTCCAGTCTTCTCTCCAGAGTCTGTGAGTATCTGCTCCTCTCCACTTCTCTCAGTTCCTCTCT  
TTCCTGAGAGTCTCAGAGTCTCCTGAGGGGCTGTCACTGCTCTCCAGAGCTCTGAGTCTCTCTCTCTCTCTA  
CACTTTAGCGAGTCTTCTCAAAAGTTCCTCAGAGTCTCCTGAGGGGCTCTGAGGAGTCTCTCTCCTCTCCTCCTC  
GTCTGTGAGCTCTCTCCTCTCCTCTCCTCAGTCTTCTCCAGAGTCTCTGAGTCTCTCTGAGTCTCTCTCTCCTC  
TCATCTGAGTCTCTCAGAGTCTCCTGAGAGTCTCTCAGAGTCTCTGATCTCTCTCTCTCCTCCTCACTTATTGAG  
CCCATCAGTGAAGAGTCCAGCAGCCAGTAGATGAATATACAAGTCTCTCAGACACTTCTGAGAGGTTGATCTTTGA  
CAGACAGCGAGTCTTTGATAGAGAGCGAGCCCTGTTCACCTTATACACTGGATGAAAGGTTGAGAGTGGCGCGGTT  
CTTCTCTCAATATCAAGTGAAGCAGCTATCAAAAGGAGAGATGCTTGTGCAATTTCCCTGAGAGAAAGTGAGCCCTGATG  
CTTCTCTGTGATCTTCAAGAAAGCCGCTGAGTCTATAGAGATCTTTTGGCAATTTCCCTGAGAGAAAGTGAGCCCTGATG  
ACTCCTATGCTTTTGAACACATATAGACCTCACTCTGAGGGGTGTGAGTGTGAGCAGGGCATGTCCAGAGCCG  
CTCTGATCTTATCTTGAGTATCATCTTCAATAAGGCGACCTATGCCCTTGAGGAGGTCATCTGGGATGCTCTGAGTGG  
AATAGGGGTGCTGTCTGGGAGGGAGCACTTTGCCCTTTGGGAGGCCAGGAGTCTCTCACTAAAGTTTGGGTGAGGAA  
ATTACCTAGAGTCCGGGAGGCGCAACTCTCTCTCTCTGTTACGAATTCCTGTGAGGAGGTCATCTGGGATGCTCTGAG  
GTCATTAAAGAGAAAGTAGTAGATTTTGGCCATGCTAAAGAAATACCGTCCCTATTACCTTTCCACTCTCTTACAAGGA  
TGTCTTGAAGAGTGTGAAGAGAGAGCCAGGCCATTAATTGACACACAGATGATCGACTGCCACAGAAAGAGTCAAGCT  
CCAGTGTGCTGCCCCAGCTTCTCTCTGAGAGAGTCTAGGGCAGATCTTCTCCTGATGTTTGAAGGGGGGAGCTGCA  
GTTTCTACGTGTGGAGGCGCTGGTGAAGCTGAGAGAAACAGAGTCTTATTCATTTCTGTTCTATGTGGGTAGTAT  
GGGGTTTACCTGTTTACTTTTGGGATTTTTCAAATGCTTTTCTTATTAATAACAGGTTTAAATAGTCAAGAACTCTA  
GTTTATGACACATGAGTGCACATGATTGCTGTTTTCTGTTTTAAGAGTAACAGTTGATATTTGTGAATAACAAAAAC  
ACACCCAAACACACCAATTTGGGAAACCTTCTGCTCATTTTGTGATGTGTGACAGGTTAATGTGGTGTACTGTAGGA  
ATTTTCTGAAACTGTGAAGGAACCTGCAAGTTAAATAGTGAATAAAGTAAGAAGGATTTGATGTTTGCATTTCTCTCA  
GCTCTTGAAGTCTGTTGTTTGAAGAACTAAAGATACATACCTGGTTTTCTGGCTTACGTAAGAAGTCTGAAGAAAGTA

ACTGTAATAATAAAAGTGTCAAGTGA

500 10 NO. 2

MGDKDMPTAGMPSLLQSSSESQSCPEGEDSQSPLOIPQSSPESDDTLYPLQSPQSRSEGEDSSDPLQRPPEGKDSQSPLOIPQSSPEGDDTQSPLONSQSSPEGKDSLSPLEISQSPPEGEDVQSPLONPASSFFSSALLSIFQSSPESIQSPFEGFPQSVLOIPVSAASSSTLVISFQSSPESTQSPFEGFPQSPLOIPVSRSFSSSTLLSIFQSSPERSQRTSEGFAQSPLOIPVSSSSSTLLSLFQSSPERTQSTFEGFPQSPLOIPVSRSFSSSTLLSIFQSSPERTQSTFEGFAQSPLOIPVSPFSSTLVISFQSSPERTQSTFEGFPQSPLOIPVSSSFSSSTLLSLFQSSPERTQSTFEGFPQSPLOIPQSPSFSSSTLLSLFQSSPERTHSTFEGFPQSPLOIPMTSSSFSSSTLLSLQSSPESAQSAFEGFPQSPLOIPVSSSFYTLSSLFQSSPERTHSTFEGFPQSPLOIPVSSSSSSSTLLSLFQSSPECTQSTFEGFPQSPLOIPQSPPEGENTHSPLOIPVSPLEWEDSLSPHYFPQSPQGEDSLSPHYFPQSPQGEDSLSPHYFPQSPQGEDSLSPHYFPQSPQGEDSMSPLYFPQSPLOQGEFQSSSQSPVSISSSTPSSLRQSFPESSQSPPEGPVQSPHSPQSPPEGMHSPQSPQSPESAPEGEDSLSPLOIPQSPLEGEDSLSSLHFPQSPPEWEDSLSPHFPQFPQGEDFQSSSQSPVSISSSTSLSPQSFPESPQSPPEGPAQSPLOIPVSSFFSYTLASLLQSSHESQSPPEGPAQSPLOIPVSSFPSSSTSSSQSPVSSFPSSSTSSSKSPSPESPLQSPVISFSSSTSLSPFSEESSPVDEYTS\$SDTLLESDSLTDS\$SLIESEPLFTYTLDEKVDLARFLLKYQVKQIPITKAEMLTNISRVTGYFPVIFRKAREFIEILFGISLREVD\$DDSYVFN\$TLT\$EGCL\$DEQGM\$QNRL\$IL\$SIIFIKGT\$YASEEVI\$WDVLSGIGVRAGREHFAFGEPRELLTKVWVQEHLEYREVPNSPPRYEFLWG\$PRAHSEVIKRW\$EFLAML\$KNVPI\$TFPSSYKDALKDVEERAQAIIDT\$TOD\$STATESASSVMSP\$FSSE.

KOC gene (from Genbank) (Seq ID NO. 4)

GGTGAGACGCTTGGGTTGTAAGCTAAGACCTTTTCTTCTTCTTTTAAACAACATCTAGACAGAAAAACAAGCCTGAGATCGATTTTCACTC  
 CTGCTTCCTGATGCTGATCTTCACTGATGTTTGTGTAATTTAAAGGAGAGAGACAGAGGAGAACAAACACAGCTGAGATCCATCCATCAGCTGGATGCTT  
 TAAATTTTCTGTTTTTCTGATTAATTTTAAACAACACTCTTGACATATGACAAACCTGTATGTGGAAACCTCAGAGAAAGGCCCCCTCCGGA  
 CCTGGAAGATCTCTGAGAGACGCAAGAACCCGGATGCGGAACCTTCCTGGTGAAGCTGGCTAGGCGTGTGGAGATCTGCCGAGAGAGAGCTGGCC  
 CTCAGAGGCAATCGAGAGCGCTTTCAGGTTAAATATGAACTGCAGGGAACCCATGAGAGTTGAGCACTGGTCCCAAAAAGGCAAAAGATTCGAAACTTC  
 AGATACGAAATATCCGCGCTCATTTACAGTGGAGGCTGGATAGATTATCTAGTCAAGTATGAGATGAGAGCTGTAGACAGATGAGACCTGAC  
 GGAACCTGCAATTTGTAAATCTATTAACCTATTCAGAGAGACACAGCTAGACACAGCACTAGACAACTGAAATGSAATTCAGTTAAGAAATTTCACTGAAA  
 GTAGCCTTAATTCCTGATGAATAATGCCCCGACGAAACCCCTTGCAGAGAACCCGAGAGTCCCGGGGGCTTGGGCAAGAGGCTCCAAAGCAGGGAT  
 CTCACAGATCCGTAATCCAGAGAAACATGTGATTTTGCTCTGCCCCCTGCTGATCCCAATTTGTTCAGAGCACTATAGAAAGAGATGCCAC  
 CATTCGGAACATGACAAACAGACCCAGCTAAATATGATGTCAACCTGAAAGAAATGCGGGGGCTGCTGAGAGTGAATTCATGCTCTCTACCTC  
 GAAAGCACCTCTGGGCTGTGATGTCTATCTGAGATTTTGCATAAGAAAGCTCAAGATATTAATTCACAGAGAGATCCCTTGAAGATTTTACCTC  
 ATATTAACCTTTGTGGAAGCTTATTTGTAAGAGAGAAAGAAATCTTAAAAAATTTGAGCAGACAGAGACACTAAATTCAGATATCTCAATTGCAGGA  
 ATTAACCGCTGTATATCCAGAACGCACTATTTACAGTTAAAGCAATGTGAGACATGTGCCAAAGCTGAGAGAGAGATCATGAAAGAAATTCAGGGAGCTC  
 TATGAAATATGATTTGCTCTCTATAGAAATCTTTCAGCACTTAAATTCGATTTAATCTGAAAGCCTTGGATCTCTTCCACCACTTCAGAGATGCCAC  
 CTCACACTCGAGGGCCCCCTTCAGGCCATGACCTCTCCCTACCGGAGTTTGAAGCAATGAAACGGAGACTGTCAATCAAGTTATTCAGACTTATCAAT  
 CGGTGCATCATTCGCAAGACAGGGCCAGCAATCAAGACAGCTTCTGCTGCTGCTGCTGAGCTTCATTAATTAATGCTCCAGCGAAACACAGATCTTAA  
 GTGAGATGTGATATATCACTGAGACACAGAGGCTCAGTATTCAGAGCTCAGGAGAAATTTATGGAATAATTAAGAGAAAGAACTTTGTATGATCTTAAG  
 AAGAGTGAACCTTGAAGCTATATCAAGTGTCACTCTTTGCTGTGTGGCAGATTTATGGAAGAGAGCAAAAGGCTGATAGAACTTGTATGATTTGTTC  
 AAGTGCAGATGATTTGTCCCTCGTGCACAGACACCTGATATGAATATGACCAAGTGGTGTCCAAATATCTGTCACTTATGATCTTCCGCGAGGTGCCAG  
 AGAAAAATTCAGAAATTTCTATCACTAGTTAAAGCAACCAACAGAGAGGCTGTCCAAAGTGCACACCTACGTCAAGAGGAAATTAAGGCTCAGGA  
 AACAGCCACCAAGAGGAGATGCCAAACCAAGACAGATGCTTAAACAGATGGGCGTGAACCCCTTCCAGAAATCAGACACAGTATTTAC

100

500

1000

1500

2000



SETA ID NO. 5

$$\frac{d}{dt} \left( \frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}$$





SED ID No. 6 (C4)

GAACGTGTCAAAGCCAAAGCAAAATGCAACCCCTTTTCTGTGGCAAAATCGCTCTGTACATGTGTGACATATTGAAAAGGAAGTGTGAATGAT  
GGCGCTGTGGGTACACAGAGGTGCTGCAAGGGTAATATTATTGAAATATATATCAAAATTAACCTAACCTCAATTTTAAATCAATTTATTTAATTTT  
TTTTTCTTTTAAAGAAAGCAAGCTTTTCTAAGACTTTAAAGAAATAAAGTCTTTGGAGGTCTCAAGGTGTAGAGAGAGAGCTTTGAGGCAACCCGACA  
AAATTCACCCAGAGGAAATCTGTGGAAAGGACCTCAAGGCAATTCTGATCACTGTGTATGTCAACAGAAAGGATACCGTCTCTGAAAGGAAA  
CTCTGTACTCTCAATGCTGTGTAGCTCATACACCCATTCTCTGTGCTCACAGTTTAACTGGTTTTTGCAATACGTCTATATAAATCTCTGTCT  
CCCCCCCCAGGCAAAACAGTGTCTGTAGTATCAATCACAAAAAGAACAAAGAGAAACCAACCAACCAATCAACAAACAAAGAAAATTCACAATG  
AGAAACAAGATCAATGTACTTGTCTGTCAGCGTTTGGAAAGGAAAACAGAACCCACCAACCAACCAATCAACAAACAAAGAAAATGTGAGAAAGTAA  
AAGAAATGATTTTGTCTTTTTCATTTTGTGTATTAAGCATCAATTTACAGAAATGATTCCTTCTTTAAAAAAAATGTGAGGAAAGTAACT  
ATTATCCAAAGGTGTGGCCAGGCGTTAAATTCACAGATTTTTTTTAAAGAAAAACACAGAAAGACTACCTCAAGTGTTTTACTCTAGACACT  
TGCTGTGTGTTCCTTAGATTTTGTAAAGCTGATAGTGTGAGCAATTTTAAATTTTAAATTAATAATGATTTGAAAAAAAATATAGATATCACT  
GCCAGCCTGAGAAAGTACAGTCCAAAGTGTGACAGCTGTCTGAATGTCTTCGCTACGACAAACCAATATGACCTTCTTTTGGACAAACCTTGA  
AAATGTTTATTTT

2500

3000

3400

3412





Seq ID No: 8 (ctd)

CGGTAAATATAATTTAGAAAATAATATCAATTAACCTCACTTAACCTCAATTTTAAATCAATTAATTAATTTTTCCTTTTAAAGAGAAAGCAGGCTTT  
TCTAGACTTTTAAAGATTAAGATCTTTTGGAGGCTCAAGGTGAGAGAGCTTTGAGGCCACCCGCAAAAATTCACCCAGAGGAAATCTCTGCGA  
AGGACATCAACGGCACTTCTGGATCACTGTGTATGTCAACAGAGGATACGGTCTCCTGAAGAGAAACTGTCTACCTCAGCTGCTAGCTC  
AATACACCACTTCTCTTGGCTTCAGAGCTTTTAACTGGTTTTTGGCATCTGCTATATAATTTCTGTCTCTGTGTTATCTCTCCCTCCCTCC

250

CGTTTGGAAAGGAAACAGGAAACCAACCAATCAACCAAGAAATAATTCACAAATGAAGATTTTGTCTTTTGGATTTT  
GGTGATTAAGCCATCAATATTCAGCAAAATGATTCCTTTCTTTAAAAAAAATGAGAGAAAGTGAATTTTACCAAGGTGTGTGGCCAGGCGTT  
AAATTCACAGATTTTAAAGCAAGAAAAACAGAGAGAAAGCTACAGGTGTTTTACTCAGACCTTGCTCTGTGTGTTCCCTTAGAGATTTGT  
AAAGCTGATGATGTTGAGCAATTTTTTATTTTAAATGAATGAGTGAAGAAAAATTAAGTATCACTGCAGCTGGAGAAAGTGAAGTCACTCAAGT  
GTGCAACAGCTGTCTGAATGTCTTCGCTAGCCAAAGACAAATGTGGCTTTTGGACAAAACCTTGAAATGTTTATTTT

3283

## COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney Docket No.  
LUD 5538.1 CIP (987339)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **"ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE, AND USES THEREOF"**, the specification of which

(check one) ☒ is attached hereto.  
☐ was filed on [ as Application Serial No. or PCT International Application No.  
and was amended on \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

## Prior Foreign Application(s)

## Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) or § 365(b) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. or PCT international application in the manner provided by the first paragraph of Title 35, U.S.C. § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

_____ 09/06/1909 (Application Serial No.)	_____ April 17, 1998 (Filing Date)	_____ Pending (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Peter F. Felfe, Reg. No. 20,297; John E. Lynch, Reg. No. 20,940; Norman D. Hanson, Reg. No. 30,946; John A. Bauer, Reg. No. 32,554; James Zubok, Reg. No. 38,671; Mary Anne Schofield, Reg. No. 36,669; and James R. Crawford, Reg. No. 39,155 my attorneys with full power of substitution and revocation. Address all telephone calls to NORMAN D. HANSON, Esq. at (212) 688-9200.  
Address all correspondence to:

**FULBRIGHT & JAWORSKI L.L.P., 666 Fifth Avenue, New York, New York 10103**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor Yao-Tseng CHEN		Inventor's Signature		Date
Residence 525 East 68 <sup>th</sup> Street, New York, New York 10021		Citizenship CH		
Post Office Address 525 East 68 <sup>th</sup> Street, New York, New York 10021				
Full Name of Second Inventor Ali GURE		Inventor's Signature		Date
Residence 1275 York Avenue, New York, New York 10021		Citizenship AT		
Post Office Address 1275 York Avenue, New York, New York 10021				
Full Name of Third Inventor Solam TSANG		Inventor's Signature		Date
Residence 1275 York Avenue, New York, New York 10021		Citizenship AT		
Post Office Address 1275 York Avenue, New York, New York 10021				
Full Name of Fourth Inventor Elisabeth STOCKERT		Inventor's Signature		Date
Residence 1275 York Avenue, New York, New York 10021		Citizenship AT		
Post Office Address 1275 York Avenue, New York, New York 10021				
Full Name of Fifth Inventor Elke JAGER		Inventor's Signature		Date
Residence Steinbacher Hohl2-28, 60488 Frankfurt AM Main, Germany		Citizenship DE		
Post Office Address Steinbacher Hohl2-28, 60488 Frankfurt AM Main, Germany				
Full Name of Sixth Inventor Alexander KNUTH		Inventor's Signature		Date
Residence Steinbacher Hohl2-28, 60488 Frankfurt AM Main, Germany		Citizenship DE		
Post Office Address Steinbacher Hohl2-28, 60488 Frankfurt AM Main, Germany				
Full Name of Seventh Inventor Lloyd J. Old		Inventor's Signature		Date
Residence 605 Third Avenue, New York, New York 10021		Citizenship US		
Post Office Address				
Full Name of Eighth Inventor		Inventor's Signature		Date
Residence		Citizenship		
Post Office Address				